Sym004 Versus TAS-102 in Patients With mCRC
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator (control) agent.
创建时间：
2019-02-15
